Investigating pharmacological mechanisms of andrographolide on non-alcoholic steatohepatitis (NASH): A bioinformatics approach of network pharmacology
10.1016/j.chmed.2021.05.001
- Author:
Lei LI
1
;
Sheng-he LI
1
;
Jin-peng JIANG
1
;
Chang LIU
1
;
Lei LI
2
;
Li-li JI
2
Author Information
1. Key Laboratory of Quality & Safety Control for Pork, Ministry of Agriculture and Rural, Anhui Key Laboratory of Animal Nutritional Regulation and Health, College of Animal Science, Anhui Science and Technology University
2. Shanghai Key Laboratory of Compound Chinese Medicines, MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
andrographolide;
molecular docking;
network pharmacology;
non-alcoholic steatohepatitis
- From:
Chinese Herbal Medicines
2021;13(3):342-350
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the mechanisms of andrographolide against non-alcoholic steatohepatitis (NASH) based on network pharmacology, so as to provide a reference for further study of andrographolide in the treatment of NASH and other metabolic diseases. Methods: The methionine- and choline-deficient (MCD) diet-induced NASH mice were treated by administration of andrographolide, and serum transaminase and pathological changes were analyzed. The network pharmacology-based bioinformatic strategy was then used to search the potential targets, construct protein–protein interaction (PPI) network, analyze gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment, and conduct molecular docking to explore the molecular mechanisms. Results: The predicted core targets TNF, MAPK8, IL6, IL1B and AKT1 were enriched in non-alcoholic fatty liver disease (NAFLD) signaling pathway and against NASH by regulation of de novo fatty acids synthesis, anti-inflammation and anti-oxidation. Conclusion: This work provides a scientific basis for further demonstration of the anti-NASH mechanisms of andrographolide.
